Reslizumab - Teva Pharmaceuticals

Drug Profile

Reslizumab - Teva Pharmaceuticals

Alternative Names: Anti-interleukin-5 monoclonal antibody - Celltech/Schering-Plough; CDP 835; CEP-38072; CINQAERO; CINQAIR; Cinquil; CTx 55700; DCP 835; SCH 55700; TRFK-5

Latest Information Update: 17 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Celltech R&D; Schering-Plough
  • Developer Allergy and Asthma Clinical Research; Celltech R&D; Teva Pharmaceutical Industries
  • Class Antiasthmatics; Monoclonal antibodies
  • Mechanism of Action Interleukin 5 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Oesophagitis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Asthma
  • Phase III Sinusitis
  • Phase II Churg-Strauss syndrome
  • No development reported Oesophagitis

Most Recent Events

  • 13 Nov 2017 The Scottish Medicines Consortium rejects reslizumab for routine use by NHS Scotland for the treatment of Eosinophilic asthma
  • 12 Sep 2017 Phase-II clinical trials in Churg-Strauss syndrome in USA (IV) (NCT02947945)
  • 25 Jul 2017 Registered for Asthma in Australia (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top